Patritumab

Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.^[1]^[2]

Clinical trials

It is to be included in a new arm of the I-SPY 2 breast cancer trial.^[4]

^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
^ Horinouchi H (December 2016). "The prospect of patritumab for treating non-small cell lung cancer". Expert Opinion on Biological Therapy. 16 (12): 1549–1555. doi:10.1080/14712598.2016.1249846. PMID 27744717. S2CID 4035336.
^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
^ "Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer" (Press release). October 2016.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.